Therapeutic potential of the endocannabinoid system in perinatal asphyxia;Potencial terapéutico del sistema endocannabinoide en la asfixia perinatal

Revista de Neurologia

Volumn 53, Issue 12, 2011, Pages 758-764

  Alonso Alconada, Daniel ^a   Álvarez, Antonia ^a   Álvarez Granda, Lino ^b   Hilario, Enrique ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Central nervous system; Endoccannabinoid system; Hypoxia ischemia; Neuroprotection; Newborn; Perinatal asphyxia

Indexed keywords

CYTOKINE; ENDOCANNABINOID; GLUTAMIC ACID;

ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CYTOKINE RELEASE; HYPOTHERMIA; IN VITRO STUDY; IN VIVO STUDY; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; PERINATAL ASPHYXIA;

EID: 83655192477     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5312.2011157     Document Type: Article

References (89)

1. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003; 4: 873-84.
2. Di Marzo V, Bisogno T, De Petrocellis L. Endocannabinoids and related compounds: walking back and forth between plant natural products and animal physiology. Chem Biol 2007; 14: 741-56.
3. Dewey WL. Cannabinoid pharmacology. Pharmacol Rev 1986; 38: 151-78.
4. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signalling. Physiol Rev 2003; 83: 1017-66.
5. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58: 389-462.
6. Walter L, Stella N. Cannabinoids and neuroinflammation. Br J Pharmacol 2004; 141: 775-85.
7. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005; 5: 400-11.
8. Hampson AJ, Grimaldi M, Lolic M, Wink D, Rosenthal R, Axelrod J. Neuroprotective antioxidants from marijuana. Ann N Y Acad Sci 2000; 899: 274-82.
9. Mackie K. Mechanisms of CB1 receptor signalling: endocannabinoid modulation of synaptic strength. Int J Obesity 2006; 30: 19-23.
10. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-9.
11. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50: 83-90.
12. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, et al. 2-arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215: 89-97.
13. Paria BC, Dey SK. Ligand-receptor signaling with endocannabinoids in preimplantation embryo development and implantation. Chem Phys Lipids 2000; 108: 211-20.
14. Fernandez-Ruiz J, Berrendero F, Hernandez ML, Ramos JA. The endogenous cannabinoid system and brain development. Trends Neurosci 2000; 23: 14-20.
15. Berrendero F, Sepe N, Ramos JA, Di Marzo V, Fernandez-Ruiz JJ. Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period. Synapse 1999; 33: 181-91.
16. Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34: 605-13.
17. Bell MR, D'Ambra TE, Kumar V, Eissenstat MA, Herrman JL. Antinociceptive (aminoalkyl)-indoles. J Med Chem 1991; 34: 1099-110.
18. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Martinez S, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350: 240-4.
19. Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 1998; 284: 644-50.
20. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004; 247: 345-58.
21. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995; 232: 54-61.
22. Nunez E, Benito C, Pazos MR, Barbachano A, Fajardo O, Gonzalez S, et al. Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse 2004; 53: 208-13.
23. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005; 310: 329-32.
24. Onaivi ES, Ishiguro H, Gong JP, Patel S, Perchuk A, Meozzi PA, et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 2006; 1074: 514-36.
25. Onaivi ES, Ishiguro H, Gu S, Liu QR. CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity. J Psychopharmacol 2011; Mar 29 [Epub ahead of print].
26. Kozak KR, Marnett LJ. Oxidative metabolism of endocannabinoids. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 211-20.
27. Craib SJ, Ellington HC, Pertwee RG, Ross RA. A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus. Br J Pharmacol 2001; 134: 30-7.
28. Romero J, Garcia-Palomero E, Berrendero F, Garcia-Gil L, Hernandez ML, Ramos JA, et al. Atypical localization of cannabinoid receptors in white matter areas during rat brain development. Synapse 1997; 26: 317-23.
29. Biegon A, Kerman IA. Autoradiographic study of pre-and postnatal distribution of cannabinoid receptors in human brain. Neuroimage 2001; 14: 1463-8.
30. Mato S, Del Olmo E, Pazos A. Ontogenetic development of cannabinoid receptor expression and signal transduction functionality in the human brain. Eur J Neurosci 2003; 17: 1747-54.
31. Ohno-Shosaku T, Maejima T, Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 2001; 29: 729-38.
32. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science 2002; 296: 678-82.
33. Di Marzo V, Melck D, Bisogno T, De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 1998; 21: 521-8.
34. Maejima T, Hashimoto K, Yoshida T, Aiba A, Kano M. Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors. Neuron 2001; 31: 463-75.
35. Galve-Roperh I, Aguado T, Palazuelos J, Guzman M. Mechanisms of control of neuron survival by the endocannabinoid system. Curr Pharm Des 2008; 14: 279-88.
36. Gerdeman G, Lovinger DM. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol 2001; 85: 468-71.
37. Galante M, Diana MA. Group I metabotropic glutamate receptors inhibit GABA release atinterneuron-Purkinje cell synapses through endocannabinoid production. J Neurosci 2004; 24: 4865-74.
38. Domenici MR, Azad SC, Marsicano G, Schierloh A, Wotjak CT, Dodt HU, et al. Cannabinoid receptor type 1 located on presynaptic terminals of principal neurons in the forebrain controls glutamatergic synaptic transmission. J Neurosci 2006; 26: 5794-9.
39. Nemeth B, Ledent C, Freund TF, Hajos N. CB1 receptordependent and-independent inhibition of excitatory postsynaptic currents in the hippocampus by WIN 55,212-2. Neuropharmacology 2008; 54: 51-7.
40. Bonfoco E, Krainc D, Ankarcrona M, Nicotera P, Lipton SA. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-Daspartate or nitric oxid/superoxide in cortical cell cultures. Proc Natl Acad Sci USA 1995; 92: 7162-6.
41. Ozaita A, Puighermanal E, Maldonado R. Regulation of PI3K/Akt/GSK-3 pathway by cannabinoids in the brain. J Neurochem 2007; 102: 1105-14.
42. Volpe J. Perinatal brain injury: from pathogenesis to neuroprotection. Mental Retard Dev Disabil Res 2001; 7: 56-64.
43. Low JA. Determining the contribution of asphyxia to brain damage in the neonate. J Obstet Gynaecol Res 2004; 30: 276-86.
44. Vannuci S, Hagberg H. Hypoxia-ischemia in the immature brain. J Exp Biol 2004; 207: 3149-54.
45. De Hann M, Wyatt JS, Roth S, Vargha-Khadem F, Gadian D, Mishki M. Brain and cognitive-behavioural development after asphyxia at term birth. Dev Sci 2006; 9: 350-8.
46. Torfs CP, van den Berg B, Oechsli FW, Cummins S. Prenatal and perinatal factors in the etiology of cerebral palsy. J Pediatr 1990; 116: 615-9.
47. Maneru C, Junque C, Botet F, Tallada M, Guardia J. Neuro-psychological long-term sequelae of perinatal asphyxia. Brain Int 2001; 15: 1029-39.
48. Yager JY, Armstrong EA, Black AM. Treatment of the term newborn with brain injury: simplicity as the mother of invention. Pediatr Neurol 2009; 40: 237-43.
49. Hilario E, Alvarez A, Alvarez FJ, Gastiasoro E, Valls-i-Soler A. Cellular mechanisms in perinatal hypoxic-ischemic brain injury. Curr Pediatr Rev 2006; 2: 131-41.
50. Edwards AD, Yue X, Cox P, Hope PL, Azzopardi DV, Squier MV, et al. Apoptosis in the brains of infants suffering intra-uterine cerebral injury. Pediatr Res 1997; 42: 684-9.
51. Dammann O, Leviton A. Brain damage in preterm newborns: biological response modification as a strategy to reduce disabilities. J Pediatr 2000; 136: 433-6.
52. Grow J, Barks JD. Pathogenesis of hypoxic-ischemic cerebral injury in the term infant: current concepts. Clin Perinatol 2002; 29: 585-602.
53. Walton M, Connor B, Lawlor P, Young D, Sirimanne E, Gluckman P, et al. Neuronal death and survival in two models of hypoxicischemic brain damage. Brain Res Rev 1999; 29: 137-68.
54. Ferriero DM. Neonatal brain injury. N Engl J Med 2004; 351: 1985-95.
55. Taylor DL, Edwards AD, Mehmet H. Oxidative metabolism, apoptosis and perinatal brain injury. Brain Pathol 1999; 9: 93-117.
56. Hilario E, Canavate ML, Lacalle J, Alonso-Alconada D, Lara-Celador I, Alvarez-Granda L, et al. Cell death. A comprehensive approximation. Delayed cell death. In Mendez-Vilas A, Diaz J, eds. Microscopy: science, technology, applications and education. Microscopy Book Series no. 4, vol. 2. Badajoz: Formatex Research Center; 2010. p. 1025-32.
57. Alonso-Alconada D, Alvarez A, Hilario E. Cannabinoids as a neuroprotective strategy in perinatal hypoxic-ischemic injury. Neurosci Bull 2011; 27: 275-85.
58. Waksman Y, Olson JM, Carlisle SJ, Cabral GA. The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J Pharmacol Exp Ther 1999; 288: 1357-66.
59. Klein TW, Lane B, Newton CA, Friedman H. The cannabinoid system and cytokine network. Proc Soc Exp Biol Med 2000; 225: 1-8.
60. Grundy RI, Rabuffetti M, Beltramo M. Cannabinoids and neuroprotection. Mol Neurobiol 2001; 24: 29-51.
61. Mechoulam R, Panikashvili D, Shohami E. Cannabinoids and brain injury: therapeutic implications. Trends Mol Med 2002; 8: 58-61.
62. Fernandez-Lopez D, Martinez-Orgado J, Nunez E, Romero J, Lorenzo P, Moro MA, et al. Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats. Pediatr Res 2006; 60: 169-73.
63. Martinez-Orgado J, Fernandez-Lopez D, Lizasoain I, Romero J. The seek of neuroprotection: introducing cannabinoids. Recent Pat CNS Drug Discov 2007; 2: 131-9.
64. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K, et al. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 1999; 19: 2987-95.
65. Louw DF, Yang FW, Sutherland GR. The effect of delta-9-tetrahydrocannabinol on forebrain ischemia in rat. Brain Res 2000; 857: 183-7.
66. Braida D, Pozzi M, Sala M. CP 55,940 protects against ischemiainduced electroencephalographic flattening and hyperlocomotion in Mongolian gerbils. Neurosci Lett 2000; 296: 69-72.
67. Mauler F, Hinz V, Augstein KH, Fassbender M, Horvath E. Neuroprotective and brain edema reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271. Brain Res 2003; 989: 99-111.
68. Leker RR, Gai N, Mechoulam R, Ovadia H. Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210. Stroke 2003; 34: 2000-6.
69. Hayakawa K, Mishima K, Abe K, Hasebe N, Takamatsu F, Yasuda H, et al. Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism. Neuroreport 2004; 15: 2381-5.
70. Parmentier-Batteur S, Jin K, Mao XO, Xie L, Greenberg DA. Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J Neurosci 2002; 22: 9771-5.
71. Van der Stelt M, Veldhuis WB, van Haaften GW, Fezza F, Bisogno T, Bar PR, et al. Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J Neurosci 2001; 21: 8765-71.
72. Panikashvili D, Shein NA, Mechoulam R, Trembovler V, Kohen R, Alexandrovich A, et al. The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis 2006; 22: 257-64.
73. Schomacher M, Muller HD, Sommer C, Schwab S, Schabitz WR. Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia. Brain Res 2008; 1240: 213-20.
74. Melis M, Pillolla G, Bisogno T, Minassi A, Petrosino S, Perra S, et al. Protective activation of the endocannabinoid system during ischemia in dopamine neurons. Neurobiol Dis 2006; 24: 15-27.
75. Zani A, Braida D, Capurro V, Sala M. D9-tetrahydrocannabinol (THC) and AM 404 protect against cerebral ischaemia in gerbils through a mechanism involving cannabinoid and opioid receptors. Br J Pharmacol 2007; 152: 1301-11.
76. Degn M, Lambertsen KL, Petersen G, Meldgaard M, Artmann A, Clausen BH, et al. Changes in brain levels of N-acylethanolamines and 2-arachidonoylglycerol in focal cerebral ischemia in mice. J Neurochem 2007; 103: 1907-16.
77. Alonso-Alconada D, Alvarez FJ, Alvarez A, Mielgo VE, Goni-de-Cerio F, Rey-Santano MC, et al. The cannabinoid receptor agonist WIN 55,212-2 reduces the initial cerebral damage after hypoxic-ischemic injury in fetal lambs. Brain Res 2010; 1362: 150-9.
78. Fernandez-Lopez D, Pazos MR, Tolon RM, Moro MA, Romero J, Lizasoain I, et al. The cannabinoid agonist WIN55212 reduces brain damage in an in vivo model of hypoxic-ischemic encephalopathy in newborn rats. Pediatr Res 2007; 62: 255-60.
79. Fernandez-Lopez D, Pradillo JM, Garcia-Yebenes I, Martinez-Orgado JA, Moro MA, Lizasoain I. The cannabinoid WIN55212-2 promotes neural repair after neonatal hypoxiaischemia. Stroke 2010; 41: 2956-64.
80. Fernandez-Ruiz J, Romero J, Velasco G, Tolon RM, Ramos JA, Guzman M. Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol Sci 2007; 28: 39-45.
81. Ashton JC, Rahman RMA, Nair SM, Sutherland BA, Glass M, Appleton I. Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoide CB2 receptor in the brain. Neurosci Lett 2007; 412: 114-7.
82. Mauler F, Horvath E, De Vry J, Jager R, Schwarz T, Sandmann S, et al. BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury. CNS Drug Rev 2003; 9: 343-58.
83. Ni X, Geller EB, Eppihimer MJ, Eisenstein TK, Adler MW, Tuma RF. WIN 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model. Mult Scler 2004; 10: 158-64.
84. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, De Ceballos ML. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 2005; 25: 1904-13.
85. Maresz K, Carrier EJ, Ponomarev ED, Hillard CJ, Dittel BN. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 2005; 95: 437-45.
86. Fernandez-Ruiz J, Pazos MR, Garcia-Arencibia M, Sagredo O, Ramos JA. Role of CB2 receptors in neuroprotective effects of cannabinoids. Mol Cell Endocrinol 2008; 286: 91-6.
87. Castillo A, Tolon MR, Fernandez-Ruiz J, Romero J, Martinez-Orgado J. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors. Neurobiol Dis 2010; 37: 434-40.
88. Fowler CJ, Rojo ML, Rodriguez-Gaztelumendi A. Modulation of the endocannabinoid system: neuroprotection or neurotoxicity? Exp Neurol 2010; 224: 37-47.
89. Pellegrini-Giampietro DE, Mannaioni G, Bagetta G. Postischemic brain damage: the endocannabinoid system in the mechanisms of neuronal death. FEBS J 2009; 276: 2-12.